Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 11/20 | 0.38 |
| ▸ | PLAT | P00750 | 4/20 | 0.38 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.35 |
| ▸ | HPN | P05981 | 1/20 | 0.35 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 7/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863285 | 1.00 | NR3C1 (0.41) | NR3C1PLAUPLATF10TDP1 | |
| Hexamethylbenzene SCHEMBL4857417 | 0.95 | NR3C1 (0.44) | NR3C1PLAUPLATF10TDP1 | |
| Hexamethylbenzene SCHEMBL4855077 | 0.95 | NR3C1 (0.44) | NR3C1PLAUPLATF10TDP1 | |
| SCHEMBL4861259 | 0.94 | NR3C1 (0.42) | NR3C1PLAUPLATF10TDP1 | |
| SCHEMBL4853935 | 0.94 | NR3C1 (0.42) | NR3C1PLAUPLATF10TDP1 | |
| SCHEMBL4863450 | 0.94 | NR3C1 (0.43) | NR3C1PLAUPLATF10TDP1 | |
| SCHEMBL4857005 | 0.94 | NR3C1 (0.43) | NR3C1PLAUPLATF10TDP1 | |
| Benzene SCHEMBL4859250 | 0.92 | NR3C1 (0.46) | NR3C1PLAUPLATF10TDP1 | |
| Benzene SCHEMBL4859285 | 0.92 | NR3C1 (0.46) | NR3C1PLAUPLATF10TDP1 | |
| SCHEMBL15364300 | 0.91 | NR3C1 (0.47) | NR3C1PLAUPLATF10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332622-B2 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGUKU KABUSHIKI KAISHA (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20050101787-A1 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1512678-A1 | Process for preparing optically active nitro compounds and cyano compounds | Kanto Kagaku Kabushiki Kaisha (JP) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101787-A1 | Process for preparing optically active nitro compounds and cyano compounds | NOS1, NOS2, NOX1 | NR3C1 3425/4885PLAU 4771/4885PLAT 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.